MAGEA3 and neoplasm: Later, tumor vaccines comprised of melanoma–associated antigen-A3 (MAGE-A3) were used as an adjuvant to surgery in the treatment of early stage MAGE-A3+ NSCLC in a large scale phase III clinical trial.